Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $66.1 million.

  • Innate Pharma's Total Non-Current Liabilities fell 2737.53% to $66.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $66.1 million, marking a year-over-year decrease of 2737.53%. This contributed to the annual value of $74.9 million for FY2024, which is 1717.55% down from last year.
  • As of Q2 2025, Innate Pharma's Total Non-Current Liabilities stood at $66.1 million, which was down 2737.53% from $74.0 million recorded in Q4 2024.
  • Innate Pharma's 5-year Total Non-Current Liabilities high stood at $112.7 million for Q2 2023, and its period low was $66.1 million during Q2 2025.
  • Over the past 5 years, Innate Pharma's median Total Non-Current Liabilities value was $91.7 million (recorded in 2021), while the average stood at $92.9 million.
  • In the last 5 years, Innate Pharma's Total Non-Current Liabilities tumbled by 9974.76% in 2021 and then surged by 1668.1% in 2023.
  • Over the past 5 years, Innate Pharma's Total Non-Current Liabilities (Quarter) stood at $91.7 million in 2021, then rose by 15.48% to $105.9 million in 2022, then decreased by 15.02% to $90.0 million in 2023, then fell by 17.79% to $74.0 million in 2024, then fell by 10.71% to $66.1 million in 2025.
  • Its Total Non-Current Liabilities was $66.1 million in Q2 2025, compared to $74.0 million in Q4 2024 and $91.0 million in Q2 2024.